Search Results

Anderson Area Cancer Center and OneOncology announced a finalized partnership to enhance the delivery of cancer services in and around Anderson, South Carolina.

Sibylla Biotech and The University of Texas MD Anderson Cancer Center announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as Folding Interfering Degraders, which disrupt the proper folding of target proteins and lead to their degradation.

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.

Replay and The University of Texas MD Anderson Cancer Center, announced that the Food & Drug Administration has issued a ‘safe to proceed’ for the Investigational New Drug application for PRAME TCR/IL-15 NK, an engineered T-Cell Receptor Natural Killer cell therapy for relapsed/refractory myeloid malignancies.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that investigators at the University of Texas MD Anderson Cancer Center’s Leukemia department presented clinical data on seclidemstat in patients with MDS and CMML at the 2024 European Hematology Association (EHA) Hybrid Congress.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA ® (olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers.

Robert L. Ferris, MD, PhD, a head and neck surgical oncologist, leading expert in cancer immunotherapy and cancer center chief executive, has been named the executive director of UNC Lineberger Comprehensive Cancer Center, and UNC system chief of oncology services, effective October 1st, announced UNC School of Medicine Dean Wesley Burks, MD.

The University of Cincinnati Cancer Center inaugurated its state-of-the-art Blood Cancer Healing Center, revolutionizing blood cancer care in the United States.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz’s investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.

CytoMed Therapeutics Limited (Nasdaq: GDTC) (“CytoMed” or the “Company”) today announced it has entered into a research collaboration agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”) in Houston, Texas.